Track market-moving stories before they get noisy

Aon (AON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experienceAdvances across Biogen’s Alzheimer’s disease portfolio underscore its leadership and continued commitment to innovation in Alzheimer’s care, spanning treatment delivery, real-world evidence and approaches targeting core pathologies, including amyloid and tau
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will present new data across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. Presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI® (lecanemab).

“Biogen remains committed to advancing innovation across Alzheimer’s care, from treatment delivery and real-world evidence generation to continued progress in addressing core pathologies, including amyloid and tau. Tau has long remained one of the most important targets in Alzheimer’s disease, and the Phase 2 CELIA topline results for diranersen reinforce the potential of tau reduction as a therapeutic approach in early Alzheimer’s disease,” said Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen. “We look forward to presenting initial data from this pioneering study as well as new data on lecanemab on the global stage at AAIC.”

Featured Scientific Sessions and Presentations

Diranersen
Diranersen is an investigational ASO that targets MAPT RNA to reduce tau production at its source, a differentiated approach to addressing abnormal tau both inside and outside neurons. At AAIC, Biogen will present clinical, biomarker and safety data that build on the May 2026 topline announcement and further characterize diranersen as the program advances toward Phase 3 development.

Topline Results from CELIA: A Phase 2 Study to Evaluate the Tau-Targeting ASO Diranersen (BIIB080) in Patients with Early Alzheimer’s Disease
Developing Topics Session: Developing Topics in Phase 2 Clinical Trials,
Tuesday, July 14, 2:00–3:30 PM BST This presentation will feature data from CELIA, an 18-month Phase 2 study evaluating diranersen, Biogen’s investigational tau-targeting ASO, in patients with early Alzheimer’s disease. The presentation will include initial clinical, biomarker and safety results from the study.

Lecanemab
Featured lecanemab sessions at AAIC will highlight continued progress in the treatment landscape for early Alzheimer’s disease, with data spanning subcutaneous administration, including at-home use, practical treatment considerations, and three-year real-world evidence from the multicenter LEADER study.

Developing Topics Session: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations
Sunday, July 12, 4:15–5:45 PM BST This session will feature presentations on the emerging clinical evidence, safety profile, practical use considerations and real-world patient experience with subcutaneous lecanemab administration in early Alzheimer’s disease.

Featured Research Session: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse U.S. Clinical Settings
Tuesday, July 14, 4:15–5:45 PM BST This session will feature new real-world evidence from the LEADER study, including findings on lecanemab use and outcomes across diverse U.S. clinical settings, once-monthly maintenance dosing, patient pathways and physician and perceived patient satisfaction with maintenance therapy.

Selected Additional Oral and Poster Presentations
The following selected presentations highlight additional areas of Alzheimer’s disease research being presented at AAIC, including lecanemab-related data. For a complete list of presentations, please refer to the AAIC scientific program.

Real-world Insights into Clinician Involvement and Testing Approaches for Mild Cognitive Impairment and Alzheimer’s
Monday, July 13, 7:30 AM–4:15 PM BST Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies in Early Alzheimer’s Disease
Monday, July 13, 7:30 AM–4:15 PM BST
Lecanemab Treatment for Alzheimer’s Disease in Real-World Clinical Practice: A Multicenter, Surveillance Safety Study from the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry
Tuesday, July 14, 9:00–10:30 AM BST
Impact of Biomarker Modalities in the Diagnostic Evaluation of Patients with Suspected Alzheimer’s Disease: A US Retrospective Study
Wednesday, July 15, 7:30 AM–4:15 PM BST Estimating the Economic Impact of Delayed Alzheimer’s Disease Progression with Lecanemab
Wednesday, July 15, 7:30 AM–4:15 PM BST Educational Program on Tau in Alzheimer’s Disease
At AAIC, Biogen will host an interactive booth offering an immersive journey into the role of tau in Alzheimer’s disease, from pathology to clinical presentation. Biogen is also expanding its educational efforts with a new e-learning module on KnowTau.com, building on the resources already available.

For more information, please see the AAIC 2026 program and visit the Biogen AAIC booth.

About diranersen (BIIB080)
Diranersen (BIIB080) is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Unlike many investigational approaches that have focused on targeting extracellular tau, diranersen is designed to reduce both intracellular and extracellular tau.

Diranersen is being investigated as a potential treatment for early Alzheimer’s disease. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease.

In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen. Diranersen was discovered by Ionis.

About the CELIA Study
CELIA is a global Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. All participants enrolled in CELIA had not previously received anti-amyloid therapy.

The study evaluated three doses of diranersen administered intrathecally over an 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months, and 115 mg every three months.

The primary endpoint of CELIA was assessment of dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) at Week 76. Secondary and exploratory endpoints included additional clinical, biomarker and imaging measures, including cerebrospinal fluid tau biomarkers and tau positron emission tomography (PET). Additional information on the CELIA study design is available in the ClinicalTrials.gov listing for the CELIA study.

An ongoing long-term extension (LTE) study is continuing to evaluate the long-term safety, tolerability and durability of diranersen in early Alzheimer’s disease.

About LEQEMBI ® (lecanemab)
LEQEMBI (lecanemab) is the result of a strategic research alliance between Eisai and BioArctic. LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble protofibril and insoluble forms of amyloid beta (Aβ). LEQEMBI is indicated in the U.S. for the treatment of Alzheimer’s disease and treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. The U.S. Food and Drug Administration (FDA) granted LEQEMBI traditional approval on July 6, 2023. Lecanemab has been approved in 53 countries and regions, including Japan, the United States, China, Europe, South Korea, Taiwan and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial treatment phase with intravenous dosing every two weeks for 18 months, intravenous maintenance dosing every four weeks has been approved in 7 countries, including the U.S., China and the UK, with applications filed in additional countries and regions. In the U.S., FDA approved LEQEMBI IQLIK™ for once-weekly subcutaneous maintenance dosing in August 2025. A supplemental Biologics License Application for LEQEMBI IQLIK as a once-weekly subcutaneous starting dose is currently under FDA Priority Review, with a Prescription Drug User Fee Act action date of August 24, 2026.

Eisai and Biogen have been collaborating on the joint development and commercialization of Alzheimer’s disease treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Please see full U.S. Prescribing Information for LEQEMBI, including Boxed WARNING and Medication Guide.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor 
This news release contains forward-looking statements, including, among others, relating to: the potential benefits, efficacy and safety of diranersen (BIIB080) and lecanemab (LEQEMBI); the potential to advance care and improve outcomes for, and address unmet needs of, patients with Alzheimer’s disease; potential regulatory discussions, submissions, decisions and approvals and the timing thereof; the anticipated benefits, risks and potential of our collaboration arrangements; the potential of our commercial business and pipeline programs, including Biogen’s Alzheimer’s disease portfolio; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and this social media channel in addition to our press releases, SEC filings, public conference calls and webcasts, as the information posted on them could be material to investors.

PubMatic (PUBM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

June 29, 2026 07:30 ET  | Source: FuelCell Energy, Inc.

DANBURY, Conn., June 29, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) announced that the Board of Directors of the Export-Import Bank of the United States (EXIM) approved a financing package on June 23, 2026, of $49 million to be disbursed in two tranches.

The first tranche, expected to disburse on June 30, 2026, provides the company with net proceeds of approximately $22 million after financing fees and customary expenses and reserves to support the delivery of five 2.8-megawatt (MW) FuelCell Energy Blocks to Gyeonggi Green Energy (GGE) in South Korea. With nearly 60 MW of installed capacity, GGE’s site is among the largest fuel cell installations in the world and serves as an important example of distributed utility-scale clean energy deployment. A second tranche is expected to be disbursed in October 2026, subject to customary closing conditions.

EXIM structured the financing under its loan guarantee program and arranged with Private Export Funding Corporation (PEFCO), supporting the export of American clean energy technology to international markets. It builds upon FuelCell Energy’s prior EXIM-supported financing completed in 2024 and 2025 and reflects continued support for the company’s export of U.S.-manufactured clean energy technology.

“EXIM’s approval validates the strength of this project, our partnership with Gyeonggi Green Energy, FuelCell Energy’s business plan, and our ability to deliver distributed utility-scale clean power globally,” said Michael Bishop, FuelCell Energy’s Chief Financial Officer. “This financing adds non-dilutive capital to support growth and provides added flexibility as we invest in scaling manufacturing capacity, pursuing strategic opportunities in global power markets and mirroring our distributed utility scale solutions to AI factories and data centers.”

FuelCell Energy manufactures its clean, baseload fuel cell technology in Torrington, Conn., supporting domestic manufacturing, U.S. supply chains, and skilled American jobs. The transaction aligns with EXIM’s mission to support U.S. manufacturing, exports, and global competitiveness. Approximately 90% of the content in FuelCell Energy Blocks is sourced from the United States.

About FuelCell Energy

FuelCell Energy, Inc. is an American clean energy technology company delivering continuous, scalable baseload power for mission critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.fuelcellenergy.com.

Contact:

Media Relations
[email protected]

Investor Relations
[email protected]

June 29 (Reuters) - Rocket Lab (RKLB.O), opens new tab said on Monday it ​would acquire satellite communications ‌provider Iridium Communications (IRDM.O), opens new tab in a cash-and-stock deal ​valued at about $8 ​billion, marking one of the ⁠biggest consolidation moves ​in the commercial space ​industry.

Iridium shareholders will receive $27 in cash and Rocket Lab ​shares, with a ​combined value of $54 per Iridium ‌share. ⁠The deal is expected to close in mid-2027.

The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.

The acquisition will ​transform Rocket ​Lab ⁠from a satellite-manufacturing and launch ​company into a ​fully ⁠integrated space business that designs, builds, launches ⁠and ​operates satellite constellations.

Reporting ​by Akash Sriram in Bengaluru; ​Editing by Joyjeet Das

Our Standards: The Thomson Reuters Trust Principles., opens new tab

June 29, 2026 06:56 ET  | Source: Golar LNG

Golar LNG's 2nd Quarter 2026 results will be released before the market opens on Thursday, August 13, 2026. In connection with this a webcast presentation will be held at 08:00am Eastern Time (1:00pm London Time) on Thursday August 13, 2026. The presentation will be available to download from the Investor Relations section at www.golarlng.com

We recommend that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call by clicking on this link. We recommend connecting 10 minutes prior to the call start. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant.

a. Listen-only live webcast link
Go to the Investors, Results Centre section at www.golarlng.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have a sound card on your computer, but no special plug ins are required to access the webcast. There is a “Help” link available on the webcast pages for anyone who may have issues accessing.

b. Teleconference

Conference call participants should register to obtain their dial in and passcode details. This process eliminates wait times when joining the call.

When you log in, you can either dial in using the provided numbers and your unique PIN, or select the “Call me” option and type in your phone number to be instantly connected to the call. Use the following link to register.

Please download the presentation material from www.golarlng.com (Investors, Results Centre) to view it while listening to the conference.

If you are not able to listen at the time of the call, you can assess a replay of the event audio for a limited time on www.golarlng.com (Investors, Results Centre).

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Highlights 

Assay results reported for 15 drill holes comprising over 5,351m of infill drilling.Consistent, wide intercepts up to 714m in width with CuEq Grades exceeding average MRE grade. Pockets of higher-grade Au and Mo, and significant localised W (Tungsten) results.Best 8 of 15 drill hole assay intersections as follows: HM138:          584m @ 0.34% CuEq (42ppm Mo, 0.040g/t Au) (0 – 584m)
incl.         72m @ 0.48% CuEq (0 – 72m)
and        128m @ 0.36% CuEq (136 – 264m)
and        170m @ 0.42% CuEq (306 – 476m) incl. 20m @ 0.70% CuEq

HM149:           428m @ 0.35% CuEq (56ppm Mo, 0.027g/t Au) (0-428m) incl.          54m @ 0.53% CuEq (26 - 80m)
and           32m @ 0.70% CuEq (92 – 124m)
and           36m @ 0.31% CuEq (142 – 178m)
and           32m @ 0.46% CuEq (186 – 218m)
and           24m @ 0.51% CuEq (252 – 276m)

HM153:            714m @ 0.31% CuEq (101ppm Mo, 0.018g/t Au) (0 – 714m)
incl.           68m @ 0.54% CuEq (294 – 362m)
and            82m @ 0.41% CuEq (386 – 468m)

HM141:             582m @ 0.25% CuEq (51ppm Mo, 0.022g/t Au) (0 – 582m)
incl.            84m @ 0.52% CuEq (234 - 318m)
and             58m @ 0.39% CuEq (334 - 392m)
and               8m @ 0.63% CuEq (566 – 574m)

HMRC001:         243m @ 0.40% CuEq (98ppm Mo, 0.020g/t Au) (0 – 243m) HM137:              162m @ 0.46% CuEq (50ppm Mo, 0.034g/t Au) (6 – 168m) HM139:                65m @ 0.55% CuEq (32ppm Mo, 0.060g/t Au) (140 - 205m) HMRC002:           24m @ 0.68% CuEq (110ppm Mo, 0.016g/t Au) (92 -116m) LUXEMBOURG, June 29, 2026 (GLOBE NEWSWIRE) -- Koryx Copper S.A. (TSX:KRY.V) (NSX:KYX) (OTCQB:KRYXF) (“Koryx” or the "Company") is pleased to announce assay results from 15 drill holes (5,351m) received as part of the ongoing infill and expansion drill program on the wholly-owned Haib Copper Project (“Haib” or the “Project”) in southern Namibia.

The Haib deposit is a massive, disseminated porphyry copper (Cu) deposit with associated molybdenum (Mo) and gold (Au). Haib is envisaged to produce a Cu and Mo concentrate via large-scale open pit mining and mainly conventional crushing, milling and sulphide flotation with the potential for additional copper cathode production via oxide heap leaching. Ongoing process flow sheet optimization is aimed at improving project economics whilst reducing technical risk.

Heye Daun, Koryx Copper’s President and CEO commented: “This is another excellent set of drill results from our ongoing 15-rig drill program. Very wide intersections at good grades exceeding 0.3% CuEq, and mostly starting from surface, indicates the potential for further improvements of our mineral resource. In conjunction with the recently announced process flow sheet enhancements, we expect the economics of the Haib project to improve significantly in the upcoming PFS which is on track to be published before the end of 2026.”

Figure 1: Plan view indicating recent drill hole locations. Results indicated in black are shown on the long section below

Figure 2. Long section showing fifteen drillhole intersections relative to the model for Cu mineralization

Discussion of Results

Target 1

HM135 was drilled as an infill hole in the northwest of Target 1, immediately south of the Volstruis River. Cu and Mo results are in line with expectations.

HM137 was drilled as an infill hole targeting the high-grade centre of Target 1 Cu mineralisation. Cu and Mo grades are in line with expectations. Notably, broad W intersections occur within the first 100m, including 4m at 0.12% W from 46m down the hole and a further 20m at 0.03% W. W has been intersected in several other Target 1 holes. Its presence is somewhat anomalous given that W is generally regarded as a proximal metal in porphyry systems. It’s presence in the upper portions of Target 1 holes remains under investigation.

HM139 is in the south of Target 1 and was drilled to test the southward extension and limit of Cu mineralisation. Results are significant with high-grade Cu-Au mineralisation intersected in the lower part of the hole, which was not encountered in previous drilling, and indicates a potential southward extension of Target 1 exceeding 100m. The hole was stopped in mineralisation due to rig limitations, with the final 8m returning 1.13% Cu and 0.14 g/t Au. The hole will be extended using a second rig in the coming months.

HM140 was drilled approximately 140m west of HM139 along the southern limit of Target 1. Good Cu and Mo results are in line with expectations, with combined elevated grades producing multiple CuEq intervals exceeding 0.3% at regular intervals down-hole. Au is known to be elevated in this part of Target 1, and HM140 confirms this, with two 2m samples returning approximately 1g/t Au, 4m @ 0.5g/t and two separate 6m intervals returning 0.1g/t and 0.2g/t Au respectively.

HM141 was drilled on the same section line as HM140 as an infill hole to close drill spacing in the centre of Target 1. Cu and Mo results are in line with expectations for this part of the deposit.

HM149 was positioned as an infill hole for resource conversion in the centre of Target 1. The results are consistent with expectations. Mo is relatively well developed from surface, peaking at ~350 m downhole before declining to low levels. W is also present, with intersections of 6 m at 0.01% W, 4 m at 0.09% W, and 2 m at 0.36% W.

MRC001 is the first reverse circulation hole completed at Haib, drilled as an infill hole in the southeast of Target 1. While intersection widths broadly match expectations, both Cu and Mo grades are above expectations.

Target 2

HM138 was drilled as an infill hole in the eastern central portion of Target 2. Cu results are excellent, with multiple wide CuEq intervals exceeding 0.36%. Au is the most significant outcome of this hole, with deeper portions returning 6m at 0.5g/t Au and a further 20m at 0.42g/t Au, the latter including a 2m sample at 1.13g/t Au and a 2m sample at 1.96 g/t Au. Thes two broader intersections represent the highest Au metal intersections recorded at Haib to date. Data density to the east and west of HM138 remains low, and the lateral extent of this Au-enrichment has not yet been established.

HM143 is located in the southern central portion of Target 2, with partial results previously reported. Cu grades are in line with expectations; however, wide, high-grade Mo mineralisation materially elevates the CuEq grade, producing intervals as wide as 230m at ≥0.34% CuEq containing narrower high-grade intervals within. Au is essentially absent.

HM144 was drilled in the northern central portion of Target 2 to test the possible surface expression of good intersections encountered at depth in nearby holes. Results indicate that HM144 is located outside the limit of economic Cu mineralisation in Target 2, with Mo practically absent.

HM153 is an infill hole drilled through the mid-depth mineralisation of Target 2. Results correlate well with the current resource model, with good to excellent Mo mineralisation maintained across the full drilled extent.
HMRC003 is an infill reverse circulation hole on the northern edge of Target 2. Cu results are in line with expectations and show strong correlation with the existing grade shell models.

Target 3

HM148 is an in-fill hole in the west of Target 4. This area is known to be well mineralised with respect to Mo, and the results reflect this. Overall, Cu and Mo assay results correlate well with the current grade shell model for Target 4.

HMRC002 is an infill reverse circulation hole drilled in Target 4 near the southern contact of the East-West Structural Zone (EWSZ). While Cu and Mo results are in line with expectations, the results do indicate that a minor positional adjustment to the EWSZ boundary will be required in the resource model, but this does not materially affect the mineralisation interpretation.

Table of Significant Intersections

Hole#ZoneFrom (m)To (m)Width (m)1CuEq (%)2Cu (%)Mo (ppm)Au (g/t)HM135
Entire Hole04164160.190.17100.029Main048480.390.3690.045Main112138260.320.27470.046Including11612040.530.461060.048HM137
Entire Hole04594590.330.28660.030Main61681620.460.42500.034Including182461.121.09350.027Including4050100.680.63350.050Including546061.471.37820.085Including949621.010.93990.063Including10210421.351.28760.070Including13614040.870.80870.055Main196260640.370.32440.036Including23824240.860.75900.108Main38038660.470.323250.032Main444456120.340.203390.025HM138
Entire Hole05845840.340.30420.040Main072720.480.421030.031Including81681.091.04590.038Including545840.960.851000.103Main1362641280.360.33360.021Including16416841.621.473190.050Including194204100.440.42240.019Including25826240.910.86770.035Main3064761700.420.34420.090Including32833460.640.2870.500Including34034440.970.93190.040Including35436280.570.50660.060Including36837460.630.58740.022Including404424200.700.39280.423Including44244640.620.56930.040Main50851460.510.48540.024HM139
Entire Hole02052050.280.25210.033Main140205650.550.49320.060Including150164140.700.64370.063Including19620481.131.02180.139HM140
Entire Hole04554550.180.14390.035Main465480.380.193470.084Main728080.520.1540.510Main100110100.390.22100.220Main13414060.500.37320.155Main278346680.300.28430.012Main418434160.350.30540.036HM141
Entire Hole05825820.250.21510.022Main106138320.310.25990.033Including10611260.630.521350.075Main158176180.300.26620.027Main184210260.310.26660.027Main234318840.520.441630.030Including234244100.650.581200.038Including25025661.181.091240.064Including27027441.231.141580.054Including30431280.600.57320.026Main334392580.390.36340.028Including342358160.590.54490.045Main56657480.630.59450.036HM142
Entire Hole03633630.150.12550.017Main160202420.360.262200.029Including16016440.640.121,3600.028HM1433
Entire Hole07067060.260.211110.018Main162260.430.263780.040Main3460260.340.261820.018Main1122261140.340.203350.021Including17418280.440.245180.019Including208226180.660.309450.026Main3585882300.340.30640.021Including410436260.510.431560.026Including490504140.680.63660.037Including53253640.530.49750.027Including54655260.510.451180.023HM144Entire Hole02112110.130.12160.009HM148
Entire Hole03113110.220.181020.013Main6274120.330.242270.017Main136180440.340.251950.017Including13613820.890.122,0700.013Including14615260.520.461210.023Main22423280.390.37210.019Main246270240.500.45970.023HM149
Entire Hole04284280.350.31560.027Main2680540.530.49380.037Including323421.171.11770.057Including465040.990.92400.066Including667260.820.78240.047Main92124320.700.66450.036Including10410841.751.67550.084Main142178360.310.27680.026Main186218320.460.41650.031Including20220860.710.611540.048Including21021221.701.63930.048Main252276240.510.45880.042Including25626040.720.641190.059Including26226860.660.60760.043Including27227640.660.59580.063Main30431280.490.265480.035Including30831240.540.161,0020.021Main388398100.310.28130.025Main412422100.390.37200.028HM153
Entire Hole07147140.310.261010.018Main242400.330.251560.020Main7090200.460.381800.029Main96120240.300.26840.020Main144172280.300.26510.021Main200268680.330.29510.017Main294362680.540.432630.021Including304322180.930.725420.027Including328344160.530.364100.025Main386468820.410.322040.023Main532556240.320.251550.019Main65866460.560.51970.030HMRC001
Entire Hole02432430.400.35980.020Main416120.810.741280.024Including101441.070.981960.028Main322402080.400.351000.020Including465260.630.542010.017Including12413060.730.613020.025Including13614480.600.511710.033Including16416840.580.491930.023Including19419840.630.58700.029Including23624040.520.49220.027HMRC002
Entire Hole02432430.150.13310.013Main92116240.680.631100.016Including10811681.131.091120.010Main126146200.310.251300.023HMRC003
Entire Hole01381380.290.27450.010Main076760.370.33690.011Including3646100.610.58610.012          True widths are unknown. Widths are interval widths and not true widths. The reported intervals are calculated using the following parameters: Only CuEq (%) was used to determine the intervals.The target composite grade is ≥0.30% CuEq.Composites start and end with samples ≥0.30% CuEq.Grades between 0.20% and 0.30% are included in interval but generally constitute <40% of the interval.Consecutive samples between 0.20% and 0.30% should be fewer than 5 samples (10m).Grades below 0.20% are included but generally constitute <20% of the interval.Consecutive grades <0.2% should be fewer than 2 samples (4m). Mineral Resource (MRE) copper equivalent (CuEq%) values have been calculated using commodity type and price considering the relevant recovery rate. The following metal prices were used Cu US$4.54/lb; Mo US$22.68/lb; Au US$4,000/oz along with the following recoveries indicated from test work, Cu 89%; Mo 65% and Au 50%. The CuEq was then calculated using CuEq = [(Cu grade/100 * 0.89 Cu recovery * 2204.62 * $4.54 Cu price/lb) + (Mo ppm/1000000 * 0.65 Mo recovery * 2204.62 * $22.68 Mo price/lb) + (Au grade * 0.50 Au recovery * 4000 Au price/oz / 31.1035)] / [0.89 Cu Recovery * 2204.62 * $4.54 Cu price/lb]Partial results previously reported Qualified Persons

Mr. Dean Richards Pr.Sci.Nat., MGSSA – BSc. (Hons) Geology is the Qualified Person for the Haib Copper Project and has reviewed and approved the scientific and technical information in this news release and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr. Sci. Nat. No. 400190/08).Mr. Richards is independent of the Company and its mineral properties and is a Qualified Person for the purposes of National Instrument 43-101.

About Koryx Copper S.A.

Koryx Copper S.A. is a Luxembourg domiciled copper development Company focused on advancing its 100% owned Haib Copper Project in Namibia whilst also building a portfolio of copper exploration licenses in Zambia. Haib is a large copper porphyry deposit in southern Namibia with significant gold and molybdenum credits and a long history of exploration and project development by multiple operators.

More than 140,000m of drilling has been conducted at Haib since the 1970’s with significant exploration programs led by companies including Falconbridge (1964), Rio Tinto (1975), Teck (2014) and Koryx Copper (2021-2026). Extensive further drilling, metallurgical testing and various technical studies have been completed at Haib. Additional studies are underway aiming to demonstrate Haib as a future long-life, low-cost, low-risk open pit, sulphide milling and flotation copper project with additional heap leach potential.

Mineralisation at Haib is typical of a porphyry copper deposit and is dominantly chalcopyrite with minor bornite and chalcocite present and only minor secondary copper minerals at surface due to the arid environment. Haib is one of only a few examples of a Paleoproterozoic porphyry copper deposit in the world. Due to its age, the deposit has been subjected to multiple metamorphic and deformation events but still retains many of the classic mineralisation and alteration features typical of these deposits.

Further details of the Haib Copper Project are available in the technical report titled “March 2026 Mineral Resource Estimate Haib Copper Project, Namibia, National Instrument 43-101 Technical Report” dated effective March 16, 2026. The report and other information are available on the Company's website at www.koryxcopper.com and under the Company's profile on SEDAR+ at www.sedarplus.ca.

Additional information is also available by contacting the Company:

Julia Becker
Corporate Communications
[email protected]
+1-604-785-0850

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the future or prospects of the Haib project or the Company, including prospective production rates and life-of-mine, the timing of publishing a PFS, the commencement of trading of the Shares under the new Company name, and the effective date of the new CUSIP and ISIN assigned to the Shares. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect ", "is expected ", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management discussion and analysis. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/98b151ef-90aa-4b59-8cee-d8135e4a31e2

https://www.globenewswire.com/NewsRoom/AttachmentNg/87947637-7701-43b2-aff1-5aed3e970f7a

Workiva (WK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Ameren (AEE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

SAN DIEGO--(BUSINESS WIRE)---- $ENSG #ENSG--Robbins Geller is investigating potential violations of the federal securities laws by Ensign.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure that enables donor lungs to be assessed outside the body after procurement and before transplantation. The PMA, submitted by United Therapeutics' wholly.

Vancouver, British Columbia – TheNewswire - June 29, 2026: Headwater Gold Inc. (CSE: HWG) (OTCQX: HWAUF) (the “Company” or “Headwater”) is pleased to announce that Centerra Gold Inc. (“Centerra”) (TSX: CG) has commenced drilling at Headwater’s Crane Creek Project (“Crane Creek” or the “Project”) in western Idaho. The drill program is being operated and fully funded by Centerra pursuant to the earn-in agreement announced on December 3, 2025.

Highlights:

Centerra-Funded Drilling Underway: Approximately 3,000 metres of reverse circulation (“RC”) and core drilling has commenced, representing the first drill program under the Centerra earn-in partnership and the first drilling at the Project since the 1990’s; 

Meaningful Initial Investment: Approximately US$1.7 million of exploration expenditures are planned toward Centerra’s US$2.5 million minimum commitment in 2026; 

Testing Historical Gold Mineralization and New Targets: Drilling is designed to follow-up on areas of shallow historical gold mineralization, test below outcropping gold-bearing veins, and step out along strike away from known mineralized zones. Historical drilling at Crane Creek includes intercepts such as 62.5 m grading 1.21 g/t Au, including 8.14 g/t Au over 3.0 m in hole 96-24; and 

Large Underexplored Epithermal System: The program follows Headwater’s recent geological and geophysical work, which expanded the target footprint beyond the area of historic drilling and defined multiple new structural targets. 

Caleb Stroup, President and CEO of Headwater, states: “We are very pleased to see Centerra drilling this high-priority project. This program represents the first major test of the Project under our earn-in partnership and is expected to account for approximately US$1.7 million of partner-funded exploration toward Centerra’s US$2.5 million minimum commitment. Prior explorers identified gold mineralization at Crane Creek, including localized high-grade epithermal vein intercepts, but historical drilling was shallow and potential deeper epithermal vein targets were largely untested. The current program is designed to follow up shallow mineralization identified with historical drilling, test below known vein-controlled mineralization, and step out along strike and between zones. This is exactly the kind of partnership we seek at Headwater: meaningful discovery exposure for shareholders, funded by a technically strong partner, while preserving capital for continued generative exploration.”

2026 Crane Creek Drill Program:

Centerra has commenced an approximate 3,000 metre drill program at Crane Creek (Figure 1), consisting of up to 15 RC holes and five diamond core holes. The program is designed to test multiple target areas generated from the integration of historical drilling, surface sampling, geologic mapping and recently completed geophysical surveys. The program is expected to represent approximately US$1.7 million in exploration expenditures toward Centerra’s US$2.5 million minimum commitment under the earn-in agreement (Table 1).

Click Image To View Full Size

  Figure 1: Location of the Crane Creek Project in western Idaho with respect to the Crane Creek Graben, a major extensional fault system which hosts the Nutmeg Mountain epithermal gold deposit2 and lies approximately 40 km south of the recently discovered copper porphyry belt centered on the Hercules project.

The RC portion of the drill program is designed to test multiple prospective targets across the Project, including areas of known historical mineralization, along-strike extensions, and newly defined structural targets. As the first diamond core program at the Project, the core holes are designed to verify historical intercepts and provide important geological information to better understand the geological setting, including the relationship between gold mineralization and the underlying basalt unit.

Historic drilling at Crane Creek was mainly completed between 1984 and 1996 and consisted predominantly of shallow RC drilling in areas of outcropping gold-bearing epithermal quartz veins. Historical drilling in these areas completed by several previous operators encountered broad zones of low-grade gold mineralization as well as localized high-grade vein intercepts such as 62.5 m grading 1.21 g/t Au, including 8.14 g/t Au over 3.0 m in hole 96-243 (Golconda Resources, 1996). Many historical drill holes were terminated shortly after intersecting an underlying basalt unit, leaving the potential for deeper, basalt-hosted, epithermal veins largely untested.

Recent work by Headwater has significantly expanded the target concept beyond the historically drilled area. Airborne magnetic and radiometric surveys, together with ground gravity data, define a broader alteration and structural footprint across the Project, including a 4 kilometre by 2 kilometre potassium anomaly, interpreted as illite-adularia alteration, and multiple north-northwest-trending structural breaks interpreted as prospective fault-hosted vein targets (Headwater news release - September 8, 2025).

Centerra Earn-In Agreement:

The Crane Creek drill program is being completed under the earn-in agreement announced December 3, 2025. Centerra is the operator during the earn-in period and may earn up to a 70% interest in the Project through staged exploration expenditures and technical milestones.

Table 1: Principal Structure of the Earn-In Agreement:

Stage

Expenditures (US$)

Centerra Interest (%)

Time for Each Stage

Minimum Commitment

$2,500,000

0%

3 Years
from October 14, 2025

Stage 1

$10,000,0001

51%2

4 Years

from October 14, 2025

Stage 2

+$15,000,000                            +1% to 2% NSR 3 to HWG

60%

4 Years

from commencement of Stage 2

Stage 3

Completion of Preliminary Economic Assessment Report4

70%

2 years

from commencement of Stage 3

1. Stage 1 is inclusive of the Minimum Commitment of US$2,500,000.

2. If Centerra completes Stage 1 but not Stage 2, its ownership interest in the Project is reduced to 49% and Headwater retains the right to purchase the interest at a mutually agreed price or, if a price cannot be mutually agreed within a specified period, for fair value that will be determined based on an agreed-upon process.

3. Upon completion of Stage 2, Headwater will be ceded a 2% NSR royalty on royalty-free claims which are 100%-owned by Headwater and a 1% NSR royalty on land subject to existing underlying royalties.

4. In order to acquire the additional 10% interest in the Project, Centerra shall be required to sole fund the completion of a Preliminary Economic Assessment Report reflecting a mineral resource of not less than 1,000,000 oz gold equivalent.

Centerra has committed to fund a minimum of US$2.5 million in exploration expenditures within the first three years of the agreement. The current program is expected to represent approximately US$1.7 million of this minimum commitment. The agreement provides a pathway for up to US$25 million in partner-funded exploration expenditures while preserving meaningful long-term exposure for Headwater.

About the Crane Creek Project:

The Crane Creek Project is located in western Idaho, approximately 18 km northeast of the town of Weiser and 90 km northwest of Boise, with a paved county road less than 1 km from the southern property boundary. The Project is fully permitted for drilling under a Notice of Intent with the Bureau of Land Management (“BLM”) and a Plan of Operation with the Idaho Department of Lands. Crane Creek comprises approximately 1,240 hectares, consisting of 123 unpatented federal mining claims on BLM land, a 640-acre State of Idaho minerals lease and a private lease.

The Project encompasses an array of mineralized epithermal quartz veins within a broad gold and trace element geochemical anomaly and features characteristics of a well-preserved low-sulfidation epithermal system, including historical mercury workings, widespread opaline silica and chalcedonic quartz veins. This alteration cell is located approximately 8 km northwest along trend of the Nutmeg Mountain gold project (Figure 1; 1,006,000 oz Au Indicated, 275,000 oz Au Inferred1,2) owned by NevGold Corp. Historical drilling primarily tested shallow near-surface mineralization in two main areas of outcropping gold-bearing quartz veins, leaving the potential for high-grade epithermal veins along strike and at depth largely untested.

About Headwater Gold:

Headwater Gold Inc. (CSE: HWG, OTCQX: HWAUF) is a technically driven mineral exploration company focused on exploring for and discovering high-grade precious metal deposits in the Western USA. Headwater is actively exploring one of the world’s most well-endowed, mining-friendly jurisdictions, with a goal of making world-class precious metal discoveries. The Company has a large portfolio of epithermal vein exploration projects and a technical team with diverse experience in capital markets and major mining companies. Headwater is systematically drill-testing several projects and has strategic earn-in agreements with OceanaGold Corporation on its TJ, Jake Creek, and Hot Creek projects, Newmont Corporation on its Spring Peak and Lodestar projects and Centerra on its Crane Creek project. In August 2022 and September 2024, Newmont and Centerra acquired strategic equity interests in the Company, further strengthening Headwater’s exploration capabilities.

For more information about Headwater, please visit the Company’s website at www.headwatergold.com.

Headwater is part of the NewQuest Capital Group, a discovery-driven investment enterprise that builds value through the incubation and financing of mineral projects and companies. Further information about NewQuest is available at www.nqcapitalgroup.com.

On Behalf of the Board of Directors

Caleb Stroup
President and CEO
+1 (775) 409-3197
[email protected]

For further information, please contact:

Brennan Zerb
Investor Relations Manager
+1 (778) 867-5016
[email protected]

Qualified Person:

The technical information contained in this news release has been reviewed and approved by Joshua Carron (SME Reg No. 042931540), a “Qualified Person” (“QP”) as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Carron is not independent, as he is the Company’s Vice President, Exploration.

Historical drill results and mineralized intercepts disclosed herein are historical in nature and were completed by previous operators.  A Qualified Person has not independently verified the historical drilling, sampling, quality control, collar locations, down-hole surveys or assay data underlying these results and Headwater has not completed sufficient work to validate the historical results.  Accordingly, the historical results should not be relied upon as current or verified exploration results.  The Company considers the historical information relevant for the purpose of identifying areas for follow-up exploration, but its reliability is uncertain because the original sampling methods, analytical procedures, laboratory certifications, chain of custody and quality control protocols are not known and therefore do not meet current industry standards.  Reported intervals should be treated as down-hole lengths and true widths are unknown.

References:

1The Qualified Person has been unable to verify the information on the adjacent properties. Mineralization hosted on adjacent and/or nearby and/or geologically similar properties is not necessarily indicative of mineralization hosted on the Company's properties. Historical resource estimates, historical drill intercepts, and historical surface samples are treated by the Company as historical in nature, and not current or NI 43-101 compliant.

2Nevgold Corp. 2023 Almaden NI43-101 Technical Report (http://www.sedarplus.ca).

3Reported grades were calculated using a 0.2 g/t cut-off grade for primary intervals and a 2 g/t cut-off grade for included intervals. Intervals correspond to downhole thickness, with insufficient information available to calculate true thickness.

Forward-Looking Statements: This news release includes certain forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements regarding planned drilling at the Crane Creek Project, future exploration expenditures by Centerra, future drill results, Centerra’s anticipated continued funding of the earn-in program, and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, risks related to the anticipated business plans and timing of future activities of the Company and Centerra, including the Company's and Centerra’s exploration plans and the proposed expenditures for exploration work on the Project, the ability of Centerra to obtain sufficient financing to fund the proposed exploration programs, the risk that Centerra will not elect to obtain any additional interest in the Project in excess of the minimum commitment, the ability of the Company to obtain the required permits, changes in laws, regulations and policies affecting mining operations, currency fluctuations, title disputes or claims, environmental issues and liabilities, as well as those factors discussed under the heading “Risk Factors” in the Company's filings with the Canadian Securities Authorities, copies of which can be found under the Company's profile on the SEDAR+ website at http://www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements, except as otherwise required by law.

 

BTU Investors Have Opportunity to Lead Peabody Energy Corporation Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

LOS ANGELES, June 29, 2026

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Peabody Energy Corporation ("Peabody" or "the Company") (NYSE: BTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 14, 2024 and May 4, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 24, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Peabody falsely led investors to believe it could reliably predict the ramp-up and growth of its Centurion mine. The Company suffered wide-ranging issues and delays at the Centurion mine. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Peabody investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/btu-investors-have-opportunity-to-lead-peabody-energy-corporation-securities-fraud-lawsuit-with-the-schall-law-firm-302812904.html

SOURCE The Schall Law Firm

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Peabody Energy Corporation (NYSE:BTU) and certain of the Company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Peabody, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

Key Details of the Peabody ($BTU) Class Action:

Lead Plaintiff Deadline: August 24, 2026Alleged Misconduct: Securities fraud relating to Peabody’s statements about the coal production at Centurion, its flagship premium hard coking coal mine.Largest Alleged Stock Drop: March 30, 2026 – 9.7% stock dropCourt: U.S. District Court for the Eastern District of MissouriAction: Contact BFA Law to discuss your rights Investors have until August 24, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Peabody common stock. The class action is pending in the U.S. District Court for the Eastern District of Missouri. It is captioned McGeachy v. Peabody, et al., No. 26-cv-01020.

Why is Peabody Being Sued for Securities Fraud?

Peabody is a producer of metallurgic and thermal coal that owns interests in 16 active coal mining operations in the United States and Australia.

According to the complaint, during the relevant period, Peabody announced it would be increasing production from its flagship premium hard coking coal mine, Centurion due to an acceleration of longwall operations. Peabody stated that shipments of Centurion’s premium hard coking coal would expand sevenfold in 2026 to 3.5 million tons and even more beyond that time. On February 5, 2026, Peabody indicated that the team was “putting the finishing touches on the Centurion mine in advance of starting longwall mining, well ahead of its original schedule.”

As alleged, in truth, the Centurion mine was facing significant commissioning challenges resulting in increased costs and volume decreases in its production.

Why did Peabody’s Stock Drop?

On March 30, 2026, Peabody announced lower sales volume from the Centurion mine due to a delivery of only 250,000 tons in the first quarter. Peabody attributed the low volume to “greater than anticipated mine commissioning challenges.”

This news caused the price of Peabody common stock to drop $3.82 per share, or 9.7%, from $39.50 per share on March 27, 2026, to $35.68 per share on March 30, 2026.

Then, on May 5, 2026, Peabody announced additional delays to the commissioning of the Centurion mine as well as increased costs and lower volume. Peabody stated it only expected to sell about 300,000 tons in the second quarter and reduced its full year sales outlook for Centurion from 3.5 million tons to 2.5 million tons.

This news caused the price of Peabody common stock to drop $1.52 per share, or 5.7%, from $26.52 per share on May 4, 2026, to $25.00 per share on May 5, 2025.

Click here for more information: https://www.bfalaw.com/cases/peabody-class-action-lawsuit.

What Can You Do?

If you invested in Peabody, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Or contact:

Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/peabody-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

CLEAR1 helps organizations verify callers before they reach a live agent, reducing fraud and streamlining support operations

, /PRNewswire/ -- CLEAR® (NYSE: YOU), the secure identity company, today announced an integration with Amazon Web Services (AWS) to bring CLEAR1, CLEAR's secure identity platform, to contact centers powered by Amazon Connect. The integration allows organizations to verify a caller's identity before or during a support interaction, designed to help reduce fraud and streamline contact center operations.

Contact centers are a critical touchpoint for customer support, but they can also be vulnerable to fraud, impersonation, and high-friction verification processes. With CLEAR1 and Amazon Connect, organizations can add identity verification earlier in the support journey before customers speak with an agent, helping teams handle sensitive requests with greater confidence and reduce time spent on manual verification steps.

"We're proud to partner with Amazon Web Services to bring our secure identity platform to contact centers at scale," said Brett Romanoff, EVP, CLEAR1. "By integrating CLEAR1 into Amazon Connect, organizations can strengthen protection against fraud while creating a more seamless experience for both agents and customers."

When a customer calls a support center powered by Amazon Connect, they can choose to verify their identity through CLEAR. If they opt in, they receive a secure SMS link to complete verification on their phone. Once verified, the call is routed to an agent, who receives the verification result in real time, helping teams move more quickly and confidently on requests such as password resets, account updates, and other high-risk actions.

"Customers expect fast, easy support the moment they call in," said Amy Belcher, Director, Global ISV Partners, AWS. "With CLEAR1 and Amazon Connect, organizations can verify callers in seconds, eliminate repetitive security questions, and let agents focus on what matters most: solving customer problems."

About CLEAR
The mission of CLEAR, the secure identity company, is to strengthen security and create frictionless experiences. With over 41 million Members and a growing network of partners across the world, CLEAR's secure identity platform is transforming the way people live, work, and travel. Whether you are traveling, at the stadium, or on your phone, CLEAR connects you to the things that make you, you—making everyday experiences easier, more secure, and friction-free. CLEAR is committed to privacy done right. Members are always in control of their own information, and we do not sell biometric or sensitive personal data. For more information, visit clearme.com.

Forward-Looking Statements
This release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes, without limitation, statements regarding the expected benefits, performance, capabilities, availability, and market adoption of CLEAR1 and its integration with Amazon Connect, including the ability to enhance identity verification, reduce fraud, streamline contact center operations, and improve customer and agent experiences. Investors are cautioned that any and such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors, including customer adoption of the Company's products and services, the successful implementation and performance of the integration, changes in market conditions, and those described in the Company's filings within the Securities and Exchange Commission, including the sections titled "Risk Factors" in our Annual Report on Form 10- K. The Company disclaims any obligation to update any forward-looking statements contained herein.

CLEAR
[email protected]

SOURCE CLEAR

Comcast said Monday it plans to separate its media and technology businesses into two publicly traded companies as it looks to better compete in a media landscape increasingly characterized by ‌pressure from streaming rivals and consolidation.

The separation, which will happen via a tax-free spin-off of NBCUniversal and Sky, is expected to be completed in about one year, and Comcast shareholders will own shares in both Comcast and NBCUniversal, the company said in a statement.

Comcast shares jumped as much as 26% in premarket trading.

Comcast co-CEO Mike Cavanagh will become CEO of NBCUniversal, while Comcast's former Chief Financial Officer Michael Angelakis will become CEO of Comcast.

Comcast's other co-CEO and chair, Brian L. Roberts, will continue to be actively involved in the leadership of both Comcast and NBCUniversal.

watch now

"The transaction we are announcing will unlock a more entrepreneurial management approach and open up a multitude of new opportunities for each business," Roberts said.

"Comcast will continue to build on its leadership in connectivity, while NBCUniversal, together with Sky, will have the scale, brands, content and financial resources to compete as a premier global media and entertainment company," Cavanagh said.

Comcast said it expects to retain a stake of up to 19.9% ownership position in NBCUniversal for up to one year after the transaction is completed, which it intends to tax-efficiently monetize over time.

It comes as Comcast's share price has plummeted 30% over the past 12 months amid significant challenges facing the media industry that are driven by the shift away from the TV bundle and toward streaming.

Comcast shares over the past year.

Earlier this year, it completed the spin-off of its portfolio of cable TV networks and digital assets, which includes CNBC and MS Now, to the separate public company Versant Media.

The media sector has seen a wave of consolidation recently, as legacy players strive for scale, with few companies going public amid the challenging environment.

Paramount Skydance completed its merger last year, and earlier this month, it won DOJ approval for a $110 billion deal for Warner Bros. Discovery. Meanwhile, Fox entered an agreement to acquire Roku for $22 billion earlier this month.

— CNBC's Lillian Rizzo contributed to this report

Disclosure: Versant is the parent company of CNBC.

Comcast said Monday that it plans to split into two companies by spinning off NBCUniversal and Sky.

Technology stocks rise as the Nasdaq Composite looks set to snap a five-day losing streak.

Breaking

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Gary Hershorn/Getty Images Comcast's stock is surging after it said it's spinning off its media businesses.

Shares jumped more than 25% in premarket trading on Monday after the company said it plans to separate its media and tech businesses into two publicly traded companies.

This will be done through a tax-free spin-off of NBCUniversal and Sky, it added.

The move is intended to give each company greater strategic focus. The company said the separation will allow both businesses to invest more effectively and pursue their own growth opportunities.

"This is a very exciting day for our company. The transaction we are announcing will unlock a more entrepreneurial management approach and open up a multitude of new opportunities for each business," Comcast co-CEO Brian Roberts said.

Earlier this year, Comcast also officially completed the spin-off of the majority of its cable networks, including CNBC and MSNBC, into a separate company called Versant Media.

Read next

Mary Hanbury You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Mary is an editor on the business news team, where she works with reporters and editors to cover sectors including technology, finance, transportation, retail, careers, and real estate.Previously, Mary was a senior retail reporter based in New York and London, covering apparel, luxury, fitness, big-box, and grocery companies. She has reported on major brands including Victoria’s Secret, Lululemon, LVMH, Costco, Dollar General, and Peloton, providing in-depth analysis of trends shaping the industry.Mary earned a master’s degree in Business Journalism from CUNY Craig Newmark Graduate School of Journalism. She has appeared on several TV and radio outlets, including BBC Business, Cheddar, and Good Morning America, and has taken part in industry panels and conferences about trends shaping the retail world.You can email her at [email protected], or follow her on Twitter or LinkedIn. 

Comcast

-

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settings

AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta’s global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).

APG-157 is Aveta's first-in-class oral immunotherapy intended to expand the benefits of immunotherapy to both immune-cold and immune-hot tumors in patients with LA-HNSCC. APG-157 has received FDA Fast Track and Orphan Drug Designations for this indication.

AVTA 30-01 builds upon previously reported Phase 2 clinical data of APG-157 monotherapy in demonstrating favorable safety, evidence of tumor-control, deep molecular responses, and encouraging event-free survival outcomes. The trial will incorporate serial Signatera testing to assess molecular residual disease (MRD) and treatment response throughout therapy and follow-up. Circulating tumor DNA (ctDNA) has emerged as one of the most promising approaches for detecting MRD and identifying recurrence earlier than conventional imaging alone.

Approximately 826 patients are expected to be enrolled across North America, Europe, Asia-Pacific, and Australia. The study includes separate randomized cohorts for resectable and unresectable locally advanced disease, each with treatment and control arms, and Signatera will be a secondary endpoint. The trial is expected to begin enrollment in 2H’26.

Global annual incidence of head and neck cancer is approximately 950,000,1 and disease recurrence remains a major cause of mortality despite advances in surgery, radiation therapy, and immunotherapy.

“Patients with locally advanced head and neck cancer continue to face substantial risks of recurrence despite aggressive treatment,” said Parag Mehta, Ph.D., founder and chief executive officer of Aveta Biomics. “We believe APG-157 has the potential to transform treatment by activating anti-tumor immunity in both immune-cold and immune-hot tumors. Incorporating serial Signatera testing into AVTA 30-01 will allow us to further validate the ctDNA findings observed in Phase 2 while generating molecular response data that will advance the understanding of treatment benefits for patients and strengthen the regulatory submission.”

This study adds to the evidence Natera continues to generate in head and neck cancer. The company recently announced a successful readout of the prospective Phase 2 SINERGY trial, supporting Signatera MRD-guided treatment in this histology.

“Growing evidence continues to demonstrate the value of Signatera MRD detection in head and neck cancer,” said Eric Matthews, general manager, biopharma, Natera. “We’re pleased to partner with Aveta on AVTA 30-01 to demonstrate how Signatera has the potential to advance the field and improve care for patients.”

References

Sun H, et al. Global burden of head and neck cancer: Epidemiological transitions, inequities, and projections to 2050. Front Oncol. 2025 Sep 25;15:1665019.About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

About Aveta Biomics

Aveta Biomics is a clinical-stage immuno-oncology company advancing first-in-class oral therapies designed to reprogram the tumor microenvironment and expand the benefits of immunotherapy to patients with immune-cold cancers. The company’s lead candidate, APG-157, has received FDA Fast Track and Orphan Drug Designations for head and neck squamous cell carcinoma and is in a global phase 3 registrational trial. APG-157 is also being evaluated across additional oncology indications including high-grade adult glioma and oral dysplasia. For more information, visit www.avetabiomics.com.

Forward-Looking Statements (for Natera)

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Forward-Looking Statements (for Aveta)

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those regarding the impact of the Fast Track Designation, the progress of our clinical trials, potential regulatory approvals, the development and commercial success of our drug candidates, and our strategic goals, reflect our current expectations and involve risks and uncertainties. Actual results may differ materially due to factors such as our ability to advance drug candidates through development and regulatory approval, clinical trial outcomes, competition, and economic conditions. Words like “may,” “will,” “could,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. We caution you not to place undue reliance on these statements, which speak only as of the date they are made. As a private company, Aveta Biomics is under no obligation to publicly update or revise any forward-looking statements to reflect new information or future events, except as required by applicable law.

More News From Natera, Inc.

Back to Newsroom

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AeroVironment, Inc. ("AeroVironment" or "the Company") (NASDAQ: AVAV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of AVAV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: June 25, 2025 to March 10, 2026

DEADLINE: July 27, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. AeroVironment misled investors over the level of competition it faced for contracts with the U.S. Space Force's Satellite Communication Augmentation Resource ("SCAR") program. Based on these facts, AeroVironment's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

CNBC's Morgan Brennan sits down with AeroVironment CEO Wahid Nawabi to discuss the expanding role of drones in defense and opportunities in the civilian market.

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of GPK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: February 4, 2025 to February 2, 2026

DEADLINE: July 6, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging downplayed the severity of reduced demand, higher costs, and inventory management struggles. Based on these facts, Graphic Packaging's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

CALX Investors Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire